Contracts › 75F40123C00184
75F40123C00184: Characterize Naloxones Clinical Use, Risks, Benefits, and Effectiveness for Reversing Opioid Overdoses in Pre-Hospital Settings. Using Qualitative and Quantitative Blood Toxicology Tests, Determine the Risks, Benefits, Effectiveness of High Dose Nal
Awarded to American College of Medical Toxicology, Inc. by Food and Drug Administration (FDA).
$4.0Mobligated
$4.0Mpotential value
29 September 2026current end date
See modifications, all subcontractors and funding in FedSift →
| Contract | 75F40123C00184 |
|---|---|
| Awardee | American College of Medical Toxicology, Inc. |
| Awarding agency | Food and Drug Administration (FDA) |
| Awarding office | FDA OFFICE OF ACQ GRANT SVCS |
| NAICS | 541990 All Other Professional, Scientific, and Technical Services |
| PSC | AN41 Health R&D Services; Health Care - Other; Basic Research |
| Place of performance | MD |
| Offers received | 1 |
| Period of performance | 25 September 2023 to 29 September 2026 |
| Potential end | 29 September 2027 |
Source: USASpending.gov (FPDS), public federal procurement data, as the agency reported it. Our record updated 03 October 2026. The solicitation date is an estimate from the end date, not a posted date.
Other expiring 541990 contracts · All expiring contracts · USASpending record